Adding atezolizumab to CP/ET as 1L treatment for ES-SCLC continued to demonstrate improved OS and a tolerable safety profile at the updated analysis, confirming the regimen as a new standard of care. Exploratory analyses demonstrated treatment benefit independent of biomarker status.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2021) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: